PTK2 and desmoid tumor: The novel treatments identified by the Desmoid Collaboration for a Cure, Dasatinib and FAK Inhibitor 14, altered the normal and desmoid tumor genotype profiles differentially, signifying a potential opportunity for directed therapies in the future.